Prostate Cell News Volume 1.17 | May 14 2010

    By
    Justin.choi
    -
    0
    19
    Prostate Cell News 1.17, May 14, 2010.
    In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  EventsSubscribe  |  Unsubscribe

    TOP STORY

    New Technology Aids in Prostate Cancer Treatment
    Researchers at Queen’s have developed a new way of performing lab tests that could improve the way doctors manage prostate cancer treatment. [Queen’s University Press Release]

    Watch Procedure Now 
    Use ALDEFLUOR® to Detect Prostate Precursor Cells
    by STEMCELL Technologies
    		 
     
    WATCH THE VIDEOSTEMCELL Technologies Inc
    		 


    SCIENCE NEWS

    Cancer: Trapping the Escape Artist
    Researchers outline how the six anti-apoptotic proteins in the Bcl-2 family are expressed differently in different cancers. [Press release from the Sanford-Burnham Medical Research Institute discussing online prepublication in Cell Death and Disease]

    Watch Procedure Now 
    Optimized Enzymes and Protocols for
    Prostate Tissue Dissociation
    by STEMCELL Technologies
    		 
     
    CLICK HERE TO LEARN MORESTEMCELL Technologies Inc
    		 


    CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

    LABORATORY RESEARCH

    Synthesis and Antitumor Properties of Selenocoxib-1 Against Rat Prostate Adenocarcinoma Cells
    Researchers used a novel strategy to combine properties of two well-studied class of compounds (selenium and COX-2 inhibitor) and examined the resulting effectiveness against prostate cancer. [Int J Cancer]

    In Vivo Through Angiogenesis and TGF-Beta Activation” target=”_blank” href=”http://www.nature.com/labinvest/journal/vaop/ncurrent/full/labinvest201090a.html” alias=”C03 Thrombospondin-1 Regulates the Normal Prostate In Vivo Through Angiogenesis and TGF-Beta Activation”>Thrombospondin-1 Regulates the Normal Prostate In Vivo Through Angiogenesis and TGF-Beta Activation
    Researchers evaluated angiogenic activity in human prostate epithelial and stromal cells treated with androgens and hypoxia in vitro. [Lab Invest]

    Indoleamine 2,3-dioxygenase (IDO) activity influence tumor growth in the TRAMP prostate cancer model
    Mice deficient in IDO expression were crossed to TRAMP mice and the time to the appearance of palpable tumors were measured. [Prostate]

    Prostate Cancer in African-American Men and Polymorphism in the Calcium-Sensing Receptor
    Researchers genotyped three CaSR single nucleotide polymorphisms for 458 African American prostate cancer cases and 248 controls from a population-based case-control study, the California Collaborative Prostate Cancer Study. [Cancer Biol Ther]

    Cyclic Bisbibenzyls Induce Growth Arrest and Apoptosis of Human Prostate Cancer PC3 Cells
    The results suggest that cyclic bisbibenzyls could be used for the development of novel therapeutic chemicals against prostate cancer. [Acta Pharmacologica Sinica]

    A Survey of the Anti-Apoptotic Bcl-2 Subfamily Expression in Cancer Types Provides a Platform to Predict the Efficacy of Bcl-2 Antagonists in Cancer Therapy
    Researchers investigated the mRNA expression levels of all six antiapoptotic Bcl-2 subfamily members in 68 human cancer cell lines using quantitative PCR techniques and measured the ability of known Bcl-2 inhibitors to induce cell death in 36 of the studied tumor cell lines. [Cell Death & Disease]

    CLINICAL RESEARCH

    The Effect of Study Arm on Prostate Cancer Treatment in the Large Screening Trial ERSPC
    Prostate cancer (PC) mortality is the most valid end-point in screening trials, but could be influenced by the choice of initial treatment if treatment has an effect on mortality. In this study, PC was compared between the screening and control arms in a screening trial. [Int J Cancer]

    Effect of Aspirin, Other NSAIDs, and Statins on PSA and PSA Velocity
    Data from 140 men with prostate cancer enrolled in a Phase II clinical trial of selenium to prevent prostate cancer progression were analyzed to determine association between aspirin, other NSAIDs, or statin use with baseline serum prostate-specific antigen (PSA) levels and PSA velocity (rate of PSA change over time) using repeated measures over an average follow-up time of 3.2 years. [Prostate]


    INDUSTRY NEWS

    Quest PharmaTech Announces Dosing Of First Patient In Its Prostate Cancer Clinical Trial
    Quest PharmaTech Inc. announced the dosing of the first patient under the Company’s recently initiated Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients. [Quest PharmaTech Inc. Press Release]

    CureVac Raises EUR 27.6 Million in Financing Round
    CureVac GmbH, the mRNA vaccine company, announced the closing of a EUR 27.6 million (US$ 35.25 million) financing round with its major shareholder, dievini Hopp BioTech holding GmbH & Co. KG. [CureVac GmbH Press Release]

    PharmaGap Announces Results of NCI Test Program
    PharmaGap Inc. is pleased to announce the latest results from testing of its lead drug compound GAP-107B8 at the National Cancer Institute in Bethesda, MD. [PharmaGap Inc. Press Release]


    POLICY NEWS

    NIH Starts to Flesh out Drug Development Program
    Lawmakers began discussing the details of a newly created drug development program at the National Institutes of Health (NIH). NIH Director Francis Collins told a Senate panel that he’s eager to get started—once the program has a budget. [National Institutes of Health, United States]

    NSF to Ask Every Grant Applicant for Data Management Plan
    Scientists seeking funding from the National Science Foundation (NSF) will soon need to spell out how they plan to manage the data they hope to collect. It’s part of a broader move by NSF and other federal agencies to emphasize the importance of community access to data. [National Science Foundation, United States]

    Notice of Funding Opportunity for a Cell Characterization Core for the National Heart, Lung and Blood Institute Progenitor Cell Biology Consortium (NOT-HL-10-109) [National Institutes of Health, United States]

    Notice of Intent to Publish Request for Applications for the Blood and Marrow Transplant Clinical Trials Network Data Coordinating Center (U10) (NOT-HL-10-108) [National Institutes of Health, United States]

    Enhancing Peer Review: Expectation for Service on NIH Peer Review and Advisory Groups (NOT-OD-10-089) [National Institutes of Health, United States]

    Request for Information: Scientific and Regulatory Issues to be Explored at an Upcoming Pluripotent Stem Cell Workshop Involving NIH and FDA (NOT-NS-10-016) [National Institutes of Health, United States]

    Drug Safety and Risk Management Advisory Committee; Notice of Meeting (Docket No. FDA-2010-N-0001) [Food and Drug Administration, United States]

    Agency Information Collection Activities; Proposed Collection; Comment Request; Experimental Study of Patient Information Prototypes (Docket No. FDA-2010-N-0184) [Food and Drug Administration, United States]


    EVENTS

    American Urological Association (AUA) 2010 Annual Meeting
    May 29-June 3, 2010
    San Francisco, United States

    International Society for Stem Cell Research (ISSCR) 8th Annual Meeting
    June 16-19, 2010
    San Francisco, United States

    21st Meeting of the European Association for Cancer Research (EACR) 
    June 26-29, 2010
    Oslo, Norway

    United Kingdom National Stem Cell Network (UKNSCN) Third Annual Scientific Conference
    July 12-14, 2010
    Nottingham, United Kingdom

    2010 World Cancer Congress
    August 18-21, 2010
    Shenzhen, China

    Joint Annual Meeting of the International Continence Society (ICS) and International Urogynecological Association (IUGA)
    August 23-27, 2010
    Toronto, Canada

    28th World Congress of Endourology and SWL
    September 1-4, 2010
    Chicago, United States

    35th European Society for Medical Oncology (ESMO) Congress
    October 8–12, 2010
    Milan, Italy

    Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


    JOB OPPORTUNITIES

    Business Development Manager Europe – Cell Therapy Products (Pall Corporation)

    Sr. Product Support and Training Specialist (CardianBCT)

    Manager/Sr. Manager, Therapeutic Cell Solutions, Process Development (Lonza)

    Recruit Top Talent
    Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.
    Visit here to post your career opportunities.

    Have we missed an important article or publication in Prostate Cell News? Click here to submit!

    Learn more about Prostate Cell News: Archives  |  Events  |  Subscribe  |  Contact Us